David A. Williams is Chief Scientific Officer and Senior Vice-President at Boston Children’s Hospital and President of the Dana-Farber/Boston Children’s Cancer and Blood Disorders Center. He also serves at the Director, Division of Hematology/Oncology, Boston Children’s Hospital. He is the Leland Fikes Chair of Pediatrics at Harvard Medical School. He is clinically active as a hematologist with a focus on bone marrow failure. He is actively involved in gene therapy trials for blood, immunodeficiency and neurological genetic diseases and has been the investigator, co-investigator or sponsor (IND holder) of four previous gene therapy trials and is sponsor, investigator or co-investigator of four current trials. He is Past President of the International Society of Experimental Hematology (ISEH) and recently served as President of the American Society of Hematology (ASH). He is co-founder of the Transatlantic Gene Therapy Consortium and the North American Pediatric Aplastic Anemia Consortium. His basic research has focused on hematopoietic stem cell biology, including genetic diseases of the blood and specifically molecular and biochemical analysis of the interaction between hematopoietic stem cells and the bone marrow supporting environment and his laboratory has been continuously funded by the National Institute of Health since 1986. He has received numerous awards and honors for his research and was elected to the National Academy of Medicine in 2003 and is a Fellow of the American Association for the Advancement of Science. He has been continuously funded by the NIH since 1986. He has multiple patents that have been licensed to biopharma and is co-founder of Orchard Therapeutics and Alerion Biosciences.